CATUG

Founded in 2021, CATUG has extensive expertise in plasmid DNA, mRNA, lipid nanoparticles (LNP) and analytical services, offering comprehensive solutions in nucleic acid based therapeutics. Headquartered in Basal, Switzerland, with additional facilities in Cambridge, Massachusetts, CATUG operates state-of-the-art laboratories and GMP-compliant manufacturing spaces to support therapeutics from discovery to commercialization. Their commitment to innovation and flexibility positions them as a trusted partner in advancing RNA and gene therapy technologies.

Europa Biosite’s subsidiaries distribute for CATUG in Austria, Belgium, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Norway, Sweden, Switzerland, the Netherlands and the United Kingdom.